Introduction
TB-500 is a name used in research-supply contexts for synthetic material related to thymosin beta-4 (T-beta-4) literature. Full-length T-beta-4 has been studied in laboratory and animal models of cell migration and tissue response. This page frames published science carefully and does not equate catalog research material with pharmaceutical products.
Chemical and structural summary
Catalog material is lyophilized research peptide associated with T-beta-4 / actin-related literature. CAS 77591-33-4 is commonly linked to thymosin beta-4 in databases; fragment preparations may have different sequences or masses. Confirm identity methods on the lot CoA.
| Catalog name | TB-500 (Thymosin Beta-4-related research material) |
|---|---|
| Category | Tissue and Repair Models |
| CAS | 77591-33-4 |
| Molecular weight note | Full thymosin beta-4 reference mass is often cited near ~4963 g/mol; research fragment identity may differ - confirm on lot CoA |
| Documentation | Lot-specific CoA available on request |
Research history and background
Thymosin beta-4 is a naturally occurring peptide discussed for roles in actin sequestration and cell motility. Laboratory studies and reviews describe experimental endpoints in wound and tissue models. Analytical chemistry literature has also described detection of TB-500-related sequences in doping-control matrices, which is relevant to identity and monitoring research rather than therapeutic use of research reagents.
Areas investigated in laboratory and preclinical research
The following themes appear in peer-reviewed literature. Inclusion here means the topic has been studied or reviewed scientifically - not that catalog materials are validated for any endpoint.
- Cell migration and actin-related laboratory assays associated with T-beta-4 biology
- Animal wound and tissue-response models reported for thymosin beta-4
- Analytical detection and metabolite characterization of TB-500-related peptides (doping-control research)
Mechanisms discussed in the literature
Literature on T-beta-4 discusses actin-binding behavior and effects on cell motility and angiogenesis-related endpoints in experimental systems. Mechanistic language in reviews should be read as model biology, not as instructions or claims for research materials sold RUO.
Key published studies and reviews
Prefer primary literature. Open links in a new tab. Always read full papers for methods and limitations.
- Goldstein AL, et al. (2012). Thymosin beta-4: a multi-functional regenerative peptide - basic properties and clinical applications (review). Expert Opin Biol Ther. PubMed 22074294.
- Malinda KM, et al. (1999). Thymosin beta-4 accelerates wound healing (rat full-thickness wound model). J Invest Dermatol. PubMed 10469335.
- Ho ENM, et al. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4. Drug Test Anal. PubMed 23084823.
Known limitations and evidence gaps
Catalog "TB-500" preparations may not be chemically identical to full-length T-beta-4 used in some papers. Sequence and mass must be verified analytically. Much of the regenerative framing in secondary literature exceeds what is supported for unregulated research materials. Human clinical validation for research reagents is not established by animal models alone.
Laboratory handling notes
General laboratory practice for lyophilized peptides includes cool, dry storage protected from moisture and light, careful reconstitution with appropriate research diluents, and documentation of lot numbers. See educational guides for process literacy - not product-specific validated stability claims.
- Storage and stability of lyophilized peptides
- Reconstitution best practices for laboratory use
- Reconstitution calculator (concentration and aliquot volume math)
- How to read a Certificate of Analysis
Regulatory status note
Materials sold by VialVibes are Research Use Only. They are not intended for human consumption, clinical administration, or veterinary use, and are not sold as FDA-approved drugs. Where the scientific literature discusses approved medicines or investigational drug programs involving the same active structure class, those regulated products remain distinct from RUO research reagents. See Research Use Only - what it means and the legal RUO policy.